Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα

Bradner JE, Hnisz D, Young RA. Transcriptional Addiction in cancer. Cell. 2017;168:629–43.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Zhuang JJ, Liu Q, Wu DL, Tie L. Current strategies and progress for targeting the “undruggable” transcription factors. Acta Pharmacol Sin. 2022. https://doi.org/10.1038/s41401-021-00852-9.

Hasserjian RP, Nardi V. Bedside to bench and back: identifying a new clinically relevant driver in pediatric acute myeloid leukemia. Blood Cancer Discov. 2022;3:173–5.

PubMed  Article  Google Scholar 

Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.

PubMed  Article  CAS  Google Scholar 

Jiao B, Ren ZH, Liu P, Chen LJ, Shi JY, Dong Y, et al. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation. Proc Natl Acad Sci USA. 2013;110:3495–500.

PubMed  PubMed Central  Article  Google Scholar 

De Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10:775–83.

PubMed  Article  CAS  Google Scholar 

Girard N, Tremblay M, Humbert M, Grondin B, Haman A, Labrecque J, et al. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells. Proc Natl Acad Sci USA. 2013;110:13522–7.

PubMed  PubMed Central  Article  Google Scholar 

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630–43.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Hussain L, Maimaitiyiming Y, Islam K, Naranmandura H. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance. Semin Oncol. 2019;46:133–44.

PubMed  Article  CAS  Google Scholar 

George B, Kantarjian H, Baran N, Krocker JD, Rios A. Tp53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci. 2021;22:10782.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Mengeling BJ, Phan TQ, Goodson ML, Privalsky ML. Aberrant corepressor interactions implicated in PML-RARα and PLZF-RARα leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. J Biol Chem. 2011;286:4236–47.

PubMed  Article  CAS  Google Scholar 

Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science. 2010;328:240–3.

PubMed  Article  CAS  Google Scholar 

Koken MHM, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A. et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)q23;q21) APL patient. Oncogene. 1999;18:1113–8.

PubMed  Article  CAS  Google Scholar 

Hussain L, Maimaitiyiming Y, Su L, Wang QQ, Naranmandura H. Phenylarsine oxide can induce degradation of PLZF-RARα variant fusion protein of acute promyelocytic leukemia. Chem Res Toxicol. 2019;32:548–50.

PubMed  Article  CAS  Google Scholar 

Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all- trans-retinoic acid. Br J Haematol. 2000;108:696–702.

PubMed  Article  CAS  Google Scholar 

Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815–8.

PubMed  Article  CAS  Google Scholar 

Wong CW, Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem. 1998;273:27695–702.

PubMed  Article  CAS  Google Scholar 

Morimoto S, Kondo T, Taya T, Matsuo H, Teramoto Y, Mizumoto C, et al. Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA. Ann Hematol. 2022;101:1129–32.

PubMed  Article  Google Scholar 

Strehl S, König M, Boztug H, Cooper BW, Suzukawa K, Zhang SJ, et al. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia. 2013;27:1606–10.

PubMed  Article  CAS  Google Scholar 

Cicconi L, Testi AM, Montesinos P, Rego E, Zhu HH, Takahashi H, et al. Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer J. 2021;11:167. https://doi.org/10.1038/s41408-021-00561-w.

PubMed  PubMed Central  Article  Google Scholar 

Geoffroy MC, de Thé H. Classic and variants APLs, as viewed from a therapy response. Cancers. 2020;12:967.

PubMed Central  Article  CAS  Google Scholar 

Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, et al. Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies. Blood Cancer Discov. 2021;2:250–65.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Wang QQ, Wang HF, Zhao JZ, Naranmandura H, Jin J, Zhu HH. Venetoclax for arsenic-resistant acute promyelocytic leukaemia. Br J Haematol. 2022;197:e58–e60.

PubMed  Article  CAS  Google Scholar 

Jiang YH, Chen YJ, Wang C, Lan YF, Yang C, Wang QQ, et al. Phenylarsine oxide can induce the arsenite-resistance mutant PML protein solubility changes. Int J Mol Sci. 2017;18:247.

PubMed Central  Article  CAS  Google Scholar 

Maimaitiyiming Y, Wang QQ, Yang C, Ogra Y, Lou Y, Smith CA, et al. Hyperthermia selectively destabilizes oncogenic fusion proteins. Blood Cancer Discov. 2021;2:388–401.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Wu HC, Rérolle D, de Thé H. PML/RARα destabilization by hyperthermia: a new model for oncogenic fusion protein degradation? Blood Cancer Discov. 2021;2:300–1.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Chao TT, Chang CC, Shih HM. SUMO modification modulates the transrepression activity of PLZF. Biochem Biophys Res Commun. 2007;358:475–82.

PubMed  Article  CAS  Google Scholar 

Kang SI, Choi HW, Kim IY. Redox-mediated modification of PLZF by SUMO-1 and ubiquitin. Biochem Biophys Res Commun. 2008;369:1209–14.

PubMed  Article  CAS  Google Scholar 

Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167–215.

PubMed  Article  CAS  Google Scholar 

Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: Implications for the clinical management of the disease. Blood Rev. 2003;17:71–97.

PubMed  Article  Google Scholar 

Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, et al. TFEB Links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021;2:162–85.

PubMed  Article  CAS  Google Scholar 

Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers. 2020;12:624.

PubMed Central  Article  CAS  Google Scholar 

Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, Cortes-Penagos C. Acute myeloid leukemia—genetic alterations and their clinical prognosis. Int J Hematol Stem Cell Res. 2017;11:328–39.

Google Scholar 

Zhou GB, Li G, Chen SJ, Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacol Sin. 2007;28:1434–49.

PubMed  Article  CAS  Google Scholar 

Gurnari C, Voso MT, Girardi K, Mastronuzzi A, Strocchio L. Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy. Int J Mol Sci. 2021;22:642.

PubMed Central  Article  CAS  Google Scholar 

Song Y, Hou J, Wan L, Liu K, Zhou C, Wei S, et al. A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia. Hematology. 2022;27:518–22.

PubMed  Article  CAS  Google Scholar 

Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, et al. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood. 2014;124:936–45.

PubMed  Article  CAS  Google Scholar 

Zhang X, Sun J, Yu W, Jin J. Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomark Res. 2021;9:33.

留言 (0)

沒有登入
gif